Targeting the epidermal growth factor receptor in colorectal carcinoma.
Colorectal cancer continues to be a common cause of death in this country, accounting for more than 55,000 deaths in 2006. The introduction of targeted biologic therapies, such as the epidermal growth factor receptor and tyrosine kinase inhibitors, has expanded the treatment options and has shown promise for patients with advanced disease. This article gives a history of the treatment of colorectal cancer, with a focus on the efficacy and toxicity of epidermal growth factor receptor inhibitors and their implications for the nursing community.
Kurtin
Sandra E
SE
Arizona Cancer Center, Tucson, Ariz 85719, USA. skurtin@umcaz.edu
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000451:nursing; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D000077341:Lapatinib; D000077544:Panitumumab; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000068818:Cetuximab; D000077156:Gefitinib